CoChat
Sign Up
Cited by 76Vector-borne infectious diseasesBrucella: diagnosis, epidemiology, treatmentBartonella species infections research

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi

Open access
Chang, Y F, Appel, M J, Jacobson, R H, Shin, S J, Harpending, P, Straubinger, R, Patrican, L A, Mohammed, H, Summers, B A·1995·Infection and Immunity
DOI 10.1128/iai.63.9.3543-3549.1995PMC PMC173491
Open this paper in CoChat — free account

Abstract

Twenty-two specific-pathogen-free beagles were vaccinated with recombinant OspA (ospA gene derived from Borrelia burgdorferi B31) alone or with adjuvant (QuilA, Montanide ISA25, or aluminum hydroxide) at 6 weeks of age. Thirteen dogs were used as nonvaccinated controls with or without adjuvant. Three dogs were kept as contact controls and received neither vaccine nor challenge. Six weeks or 6 months after the first vaccination, the vaccinated (20 of 22) and nonvaccinated dogs (13) were challenged by exposure to adult ticks (Ixodes scapularis) naturally that were infected with B. burgdorferi (tick infection rate, > or = 60%) and that were collected from Westchester County, N.Y. Protection from infection was evaluated by culture for B. burgdorferi from skin biopsies taken near the sites of tick bites. Skin biopsies were taken at monthly intervals for 3 months. B. burgdorferi was not isolated from any of the vaccinated dogs. In contrast, 12 of 13 control dogs challenged by exposure to the ticks were culture positive. The histopathology of the joint capsules 3 months after the challenge was used to evaluate protection from arthritis. Eight of 13 control dogs showed synovitis in single or multiple joints, while only 1 of the 22 vaccinated dogs had a single focus of mild inflammation in a single joint. At the time of the challenge, the vaccinated dogs had antibody to B. burgdorferi, which was demonstrable by kinetic enzyme-linked immunosorbent assay, Western blotting (immunoblotting), and a serum growth inhibition assay. The vaccinal antibody declined gradually after the challenge, especially in dogs vaccinated with OspA without adjuvants. Antibodies in the challenge control dogs were only detectable by 4 to 6 weeks after the challenge and remained at high levels until the termination of the study. Contact control dogs showed no antibody responses or histopathologic lesions and were culture negative. By Western blot analysis, antibodies to OspA first appeared in the sera of vaccinated dogs 3 weeks after the first vaccination. The absence of additional bands after the challenge suggests that infection in vaccinated dogs was blocked. Results from this study show that vaccination with recombinant OspA protected dogs against infection and disease after an experimental challenge with B. burgdorferi by exposure to ticks.

Overview

Integrity signals

Registry

Crossref · 10.1128/iai.63.9.3543-3549.1995

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 76

Related

See all

Metadata

Authors
Chang, Y. F., Appel, M. J., Jacobson, R. H., Shin, S. J., Harpending, P., Straubinger, R., Patrican, L. A., Mohammed, H., & Summers, B. A.
Affiliations
Cornell University (US)
ORCID
Venue
Infection and Immunity
Publisher
American Society for Microbiology
Published
1995-09
Volume
63
Issue
9
Pages
3543-3549
ISSN
  • 0019-9567 (ISSN-L)
  • 1098-5522
DOI
10.1128/iai.63.9.3543-3549.1995
PMC
PMC173491
OpenAlex
W1788215479
Cited by
76
References
45
Citations by year
2022: 5 · 2021: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 1
FWCI
3.25
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Infection and Immunity (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Vector-borne infectious diseases
  • Health Sciences › Medicine › Infectious Diseases › Brucella: diagnosis, epidemiology, treatment
  • Health Sciences › Medicine › Infectious Diseases › Bartonella species infections research
Keywords
Borrelia burgdorferi, Lyme disease vaccine, dogs, tick-borne diseases, Ixodes scapularis, arthritis, vaccine adjuvants, antibody response, vaccine protection, synovitis, skin biopsy culture, vaccine immunogenicity
MeSH terms
Animals, Antibodies, Bacterial, Antigens, Surface, Bacterial Outer Membrane Proteins, Bacterial Vaccines, Dogs, Female, Lipoproteins, Lyme Disease, Male, Ticks, Vaccination, Vaccines, Synthetic, Borrelia burgdorferi Group

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review